{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Clinical Evidence for BAT Inducing DNA Damage', 'Recently, a case report was published that described an extreme responder to BAT who', \"harbored deleterious ATM and BRCA2 mutations. Because this individual's tumor had an\", 'intrinsic deficiency in its ability to repair DNA damage, it was hypothesized that dsDNA', 'breaks induced by high-dose T were unable to be repaired, and BAT was therefore', 'synthetically lethal to tumor cells[60]. As part of ongoing translational work aimed at', 'understanding the drivers of response/resistance to BAT, we have performed next-generation', 'sequencing on tumor DNA from seven patients receiving BAT on the TRANSFORMER', 'clinical trial, which is testing BAT VS. enzalutamide in mCRPC patients who have progressed', 'on abiraterone [clinicaltrials.gov NCT02286921]. Consistent with the findings from the', 'aforementioned case report, we have found that the majority of patients exhibiting a PSA', 'response have detectable alteration in DNA damage repair pathway genes - further supporting', 'the induction of DNA damage as a key mechanism driving clinical responses to BAT (Figure', '7).', '100', '80', 'Biallelic DDR Mutation', '60', 'Monoalletic DDR Mutation', 'No DDR Mutation', '40', '20', '0', '-20', '-40', '-60', '-80', '-100', 'Figure 7: Percent change in PSA compared to baseline in men receiving Bipolar Androgen', 'Therapy. DDR = DNA damage response; * = truncated at 100% increase in PSA above baseline.', '1.3', 'Olaparib Background', 'Investigators should be familiar with the current olaparib (AZD2281) Investigator Brochure', '(IB).', '16(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', \"Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose [poly (ADP\", 'ribose) polymerization (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an', 'oral therapy, both as a monotherapy (including maintenance) and for combination with', 'chemotherapy and other anti-cancer agents.', 'PARP inhibition is a novel approach to targeting tumors with deficiencies in DNA repair', 'mechanisms. PARP enzymes are essential for repairing DNA single strand breaks (SSBs).', 'Inhibiting PARPs leads to the persistence of SSBs, which are then converted to the more', 'serious DNA double strand breaks (DSBs) during the process of DNA replication [61-64].', 'During the process of cell division, DSBs can be efficiently repaired in normal cells by', 'homologous recombination repair (HR). Tumors with HR deficiencies (HRD), such as', 'ovarian cancers in patients with BRCA1/2 mutations, cannot accurately repair the DNA', 'damage, which may become lethal to cells as it accumulates [64-66]. In addition, PARP is', 'involved in repairing DSB through the alternative non-homologous end-joining (NHEJ)', 'pathway, and PARP inhibitors could therefore further impair DSB repair in HR-deficient', 'tumors[67-69]. In such tumor types, olaparib may offer a potentially efficacious and less', 'toxic cancer treatment compared with currently available chemotherapy regimens.', 'BRCA1 and BRCA2 defective tumors are intrinsically sensitive to PARP inhibitors, both in', 'tumor models in vivo and in the clinic [70-72]. The mechanism of action for olaparib results', 'from the trapping of inactive PARP onto the single-strand breaks preventing their repair [73,', '74]. Persistence of SSBs during DNA replication results in their conversion into the more', 'serious DNA DSBs that would normally be repaired by HR repair. Olaparib has been shown', 'to inhibit selected tumor cell lines in vitro and in xenograft and primary explant models as', 'well as in genetic BRCA knock-out models, either as a stand-alone treatment or in', 'combination with established chemotherapies. In addition, PARP inhibitors have been shown', 'across multiple preclinical tumor models to potentiate the antitumor effects of DNA damaging', 'cytotoxic agents (e.g. alkylating agents, platinum chemotherapy) as well as radiation [72, 75-', '78]. Importantly, many of these studies have shown that the observed anti-tumor effects are', 'not restricted to cell lines with loss of HR pathway genes.', '1.3.1', 'Pre-clinical experience', 'The pre-clinical experience is fully described in the current version of the olaparib', \"Investigator's Brochure (IB).\", 'A range of tumor cell lines have been investigated using colony formation assays for', 'sensitivity to PARP inhibition with olaparib as a single agent. IC50 data were calculated for', 'each cell line across KU95, a mixed tumor type panel of 95 cancer cell lines that also', 'contained ovarian cancer cell lines (Figure 8). Cell lines representing breast, ovarian,', 'colorectal, head and neck, lung and pancreatic tumor types were screened and shown to have', 'wide-ranging cellular activity from the low nM (IC50 18 nM) to in excess of 10 M (cell lines', 'with IC50 greater than 10 M, the top concentration used, where an exact IC50 could not be', 'determined, are listed as 10 M with a zero Sd for plotting purposes).', '17(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}